The Disease-modifying Drug Candidate, SAK3 Improves Cognitive Impairment and Inhibits Amyloid beta Deposition in App Knock-in Mice

Hisanao Izumi, Yasuharu Shinoda, Takashi Saito, Takaomi C. Saido, Keita Sato, Yasushi Yabuki, Yotaro Matsumoto, Yoshitomi Kanemitsu, Yoshihisa Tomioka, Nona Abolhassani, Yusaku Nakabeppu, Kohji Fukunaga

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Alzheimer's disease (AD) is a progressive neurodegenerative disease and the most common form of elderly dementia in the world. At present, acetylcholine inhibitors, such as donepezil, galantamine and rivastigmine, are used for AD therapy, but the therapeutic efficacy is limited. We recently proposed T-type voltage-gated Ca2+ channels’ (T-VGCCs) enhancer as a new therapeutic candidate for AD. In the current study, we confirmed the pharmacokinetics of SAK3 in the plasma and brain of mice using ultra performance liquid chromatography-tandem mass spectrometry. We also investigated the effects of SAK3 on the major symptoms of AD, such as cognitive dysfunction and amyloid beta (Aβ) accumulation, in AppNL-F knock-in (NL-F) mice, which have been established as an AD model. Chronic SAK3 (0.5 mg/kg/day) oral administration for 3 months from 9 months of age improved cognitive function and inhibited Aβ deposition in 12-month-old NL-F mice. Using microarray and real-time PCR analysis, we discovered serum- and glucocorticoid-induced protein kinase 1 (SGK1) as one of possible genes involved in the inhibition of Aβ deposition and improvement of cognitive function by SAK3. These results support the idea that T-VGCC enhancer, SAK3 could be a novel candidate for disease-modifying therapeutics for AD.

Original languageEnglish
Pages (from-to)87-97
Number of pages11
JournalNeuroscience
Volume377
DOIs
Publication statusPublished - May 1 2018

Fingerprint

Amyloid
Alzheimer Disease
Pharmaceutical Preparations
Rivastigmine
Cognition
Galantamine
Therapeutics
Tandem Mass Spectrometry
Liquid Chromatography
Neurodegenerative Diseases
Protein Kinases
Glucocorticoids
Acetylcholine
Oral Administration
Dementia
Cognitive Dysfunction
Real-Time Polymerase Chain Reaction
Pharmacokinetics
Brain
Serum

All Science Journal Classification (ASJC) codes

  • Neuroscience(all)

Cite this

The Disease-modifying Drug Candidate, SAK3 Improves Cognitive Impairment and Inhibits Amyloid beta Deposition in App Knock-in Mice. / Izumi, Hisanao; Shinoda, Yasuharu; Saito, Takashi; Saido, Takaomi C.; Sato, Keita; Yabuki, Yasushi; Matsumoto, Yotaro; Kanemitsu, Yoshitomi; Tomioka, Yoshihisa; Abolhassani, Nona; Nakabeppu, Yusaku; Fukunaga, Kohji.

In: Neuroscience, Vol. 377, 01.05.2018, p. 87-97.

Research output: Contribution to journalArticle

Izumi, H, Shinoda, Y, Saito, T, Saido, TC, Sato, K, Yabuki, Y, Matsumoto, Y, Kanemitsu, Y, Tomioka, Y, Abolhassani, N, Nakabeppu, Y & Fukunaga, K 2018, 'The Disease-modifying Drug Candidate, SAK3 Improves Cognitive Impairment and Inhibits Amyloid beta Deposition in App Knock-in Mice', Neuroscience, vol. 377, pp. 87-97. https://doi.org/10.1016/j.neuroscience.2018.02.031
Izumi, Hisanao ; Shinoda, Yasuharu ; Saito, Takashi ; Saido, Takaomi C. ; Sato, Keita ; Yabuki, Yasushi ; Matsumoto, Yotaro ; Kanemitsu, Yoshitomi ; Tomioka, Yoshihisa ; Abolhassani, Nona ; Nakabeppu, Yusaku ; Fukunaga, Kohji. / The Disease-modifying Drug Candidate, SAK3 Improves Cognitive Impairment and Inhibits Amyloid beta Deposition in App Knock-in Mice. In: Neuroscience. 2018 ; Vol. 377. pp. 87-97.
@article{d424d45e28c3453dbc7ffdc8e6745df7,
title = "The Disease-modifying Drug Candidate, SAK3 Improves Cognitive Impairment and Inhibits Amyloid beta Deposition in App Knock-in Mice",
abstract = "Alzheimer's disease (AD) is a progressive neurodegenerative disease and the most common form of elderly dementia in the world. At present, acetylcholine inhibitors, such as donepezil, galantamine and rivastigmine, are used for AD therapy, but the therapeutic efficacy is limited. We recently proposed T-type voltage-gated Ca2+ channels’ (T-VGCCs) enhancer as a new therapeutic candidate for AD. In the current study, we confirmed the pharmacokinetics of SAK3 in the plasma and brain of mice using ultra performance liquid chromatography-tandem mass spectrometry. We also investigated the effects of SAK3 on the major symptoms of AD, such as cognitive dysfunction and amyloid beta (Aβ) accumulation, in AppNL-F knock-in (NL-F) mice, which have been established as an AD model. Chronic SAK3 (0.5 mg/kg/day) oral administration for 3 months from 9 months of age improved cognitive function and inhibited Aβ deposition in 12-month-old NL-F mice. Using microarray and real-time PCR analysis, we discovered serum- and glucocorticoid-induced protein kinase 1 (SGK1) as one of possible genes involved in the inhibition of Aβ deposition and improvement of cognitive function by SAK3. These results support the idea that T-VGCC enhancer, SAK3 could be a novel candidate for disease-modifying therapeutics for AD.",
author = "Hisanao Izumi and Yasuharu Shinoda and Takashi Saito and Saido, {Takaomi C.} and Keita Sato and Yasushi Yabuki and Yotaro Matsumoto and Yoshitomi Kanemitsu and Yoshihisa Tomioka and Nona Abolhassani and Yusaku Nakabeppu and Kohji Fukunaga",
year = "2018",
month = "5",
day = "1",
doi = "10.1016/j.neuroscience.2018.02.031",
language = "English",
volume = "377",
pages = "87--97",
journal = "Neuroscience",
issn = "0306-4522",
publisher = "Elsevier Limited",

}

TY - JOUR

T1 - The Disease-modifying Drug Candidate, SAK3 Improves Cognitive Impairment and Inhibits Amyloid beta Deposition in App Knock-in Mice

AU - Izumi, Hisanao

AU - Shinoda, Yasuharu

AU - Saito, Takashi

AU - Saido, Takaomi C.

AU - Sato, Keita

AU - Yabuki, Yasushi

AU - Matsumoto, Yotaro

AU - Kanemitsu, Yoshitomi

AU - Tomioka, Yoshihisa

AU - Abolhassani, Nona

AU - Nakabeppu, Yusaku

AU - Fukunaga, Kohji

PY - 2018/5/1

Y1 - 2018/5/1

N2 - Alzheimer's disease (AD) is a progressive neurodegenerative disease and the most common form of elderly dementia in the world. At present, acetylcholine inhibitors, such as donepezil, galantamine and rivastigmine, are used for AD therapy, but the therapeutic efficacy is limited. We recently proposed T-type voltage-gated Ca2+ channels’ (T-VGCCs) enhancer as a new therapeutic candidate for AD. In the current study, we confirmed the pharmacokinetics of SAK3 in the plasma and brain of mice using ultra performance liquid chromatography-tandem mass spectrometry. We also investigated the effects of SAK3 on the major symptoms of AD, such as cognitive dysfunction and amyloid beta (Aβ) accumulation, in AppNL-F knock-in (NL-F) mice, which have been established as an AD model. Chronic SAK3 (0.5 mg/kg/day) oral administration for 3 months from 9 months of age improved cognitive function and inhibited Aβ deposition in 12-month-old NL-F mice. Using microarray and real-time PCR analysis, we discovered serum- and glucocorticoid-induced protein kinase 1 (SGK1) as one of possible genes involved in the inhibition of Aβ deposition and improvement of cognitive function by SAK3. These results support the idea that T-VGCC enhancer, SAK3 could be a novel candidate for disease-modifying therapeutics for AD.

AB - Alzheimer's disease (AD) is a progressive neurodegenerative disease and the most common form of elderly dementia in the world. At present, acetylcholine inhibitors, such as donepezil, galantamine and rivastigmine, are used for AD therapy, but the therapeutic efficacy is limited. We recently proposed T-type voltage-gated Ca2+ channels’ (T-VGCCs) enhancer as a new therapeutic candidate for AD. In the current study, we confirmed the pharmacokinetics of SAK3 in the plasma and brain of mice using ultra performance liquid chromatography-tandem mass spectrometry. We also investigated the effects of SAK3 on the major symptoms of AD, such as cognitive dysfunction and amyloid beta (Aβ) accumulation, in AppNL-F knock-in (NL-F) mice, which have been established as an AD model. Chronic SAK3 (0.5 mg/kg/day) oral administration for 3 months from 9 months of age improved cognitive function and inhibited Aβ deposition in 12-month-old NL-F mice. Using microarray and real-time PCR analysis, we discovered serum- and glucocorticoid-induced protein kinase 1 (SGK1) as one of possible genes involved in the inhibition of Aβ deposition and improvement of cognitive function by SAK3. These results support the idea that T-VGCC enhancer, SAK3 could be a novel candidate for disease-modifying therapeutics for AD.

UR - http://www.scopus.com/inward/record.url?scp=85043982955&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85043982955&partnerID=8YFLogxK

U2 - 10.1016/j.neuroscience.2018.02.031

DO - 10.1016/j.neuroscience.2018.02.031

M3 - Article

C2 - 29510211

AN - SCOPUS:85043982955

VL - 377

SP - 87

EP - 97

JO - Neuroscience

JF - Neuroscience

SN - 0306-4522

ER -